An anti-TL1A has demonstrated its potential to be a best-in-class treatment for ulcerative colitis. 

Biotechnology company Spyre Therapeutics reported results from the Phase II SKYLINE trial evaluating SPY002, an extended half-life investigational antibody targeting TL1A. TL1A is an upstream cytokine implicated in chronic inflammation and fibrosis in inflammatory bowel disease (IBD). 

Initial 12-week findings demonstrated SPY002 met all key objectives, achieving a statistically significant 10.7-point reduction in Robart’s Histopathology Index (RHI).  

Secondary endpoints included clinical remission by modified Mayo Score of 33% and endoscopic improvement of 42%. 

“SPY002 demonstrated an indication-leading 10.7-point reduction in RHI and meaningful clinical remission and endoscopic outcomes in line with the anti-TL1A class and among the highest across therapeutic classes,” said Deanna Nguyen, SVP of Clinical Development and SKYLINE Study Lead.  

“Together with its target Q3-6M sub-cutaneous maintenance profile, these data build upon our impressive SPY001 results and reinforce our thesis that optimised monotherapy components are the foundation for potentially best-in-class combinations.  

“We remain on track to report Part A data for SPY003 (anti-IL-23) in Q3, which, if successful, would complete proof-of-concept for our investigational monotherapy components.  

“We are now enrolling Part B of the SKYLINE trial, which includes three combination arms with the potential to deliver best-in-disease efficacy, safety, and treatment experience.”